Allele burden thresholds

Current understanding

JAK2 V617F allele burden as a transplant eligibility and outcome predictor — emerging evidence on optimal cutoffs.

2026-10-07 — Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.: Extends the serial-monitoring argument from CALR allele burden alone to broader serial NGS profiling, since acquired TP53/KRAS/RUNX1 co-mutations — not CALR burden — drive the transplant-timing decision in CALR-mutated MPN. (novelty: 3)
2026-06-23 — A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant: MRD-guided maintenance trial operationalizes pre-/post-transplant residual disease measurement as the trigger for treatment assignment — extends allele-burden/MRD thresholds from a prognostic marker into an actionable decision rule for post-HCT therapy. (novelty: 3)
2026-03-06 — Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI): CALRSUIVI prospective observational study evaluates CALR allele burden as a molecular marker for disease progression and follow-up in CALR-mutated MPN, extending the allele-burden-monitoring paradigm beyond JAK2 V617F — though direct linkage to transplant timing/eligibility thresholds remains to be established. (novelty: 3)